Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: A systematic review of frequency and costs

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 737-745

  Moots, Robert J ^a   Mays, Robyn ^b   Stephens, Jennifer ^b   Tarallo, Miriam ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PHARMERIT INTERNATIONAL   (United States)

^c PFIZER INC   (United States)

Author keywords

Biologics; Dose escalation; Economic evaluation; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; DOSE CALCULATION; ECONOMICS; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG DOSAGE CALCULATIONS; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942909575     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. SINGH JA, FURST DE, BHARAT A et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
3. WEINBLATT ME: Rheumatoid arthritis: more aggressive approach improves outlook. Cleve Clin J Med 2004; 71: 409-13.
4. NAM JL, RAMIRO S, GAUJOUX-VIALA C et al.: Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 516-28.
5. RUBBERT-ROTH A, FINCKH A: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11 (Suppl. 1): S1.
6. BARTELDS GM, KRIECKAERT CL, NURMOHAMED MT et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
7. BARTELDS GM, WIJBRANDTS CA, NURMOHAMED MT et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
8. WOLBINK GJ, VIS M, LEMS W et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
9. van SCHOUWENBURG PA, RISPENS T, WOLBINK GJ: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72.
10. MOK CC, van der KLEIJ D, WOLBINK GJ: Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF-alpha biologics in rheumatic diseases. Clin Rheumatol 2013; 32: 1429-35.
11. TYRING S, GORDON KB, POULIN Y et al.: Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26.
12. BONAFEDE MM, GANDRA SR, FOX KM, WILSON KL: Tumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ 2012; 15: 635-43.
13. FINCKH A, DUDLER J, WERMELINGER F et al.: Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010; 77: 313-8.
14. HARAOUI B, CAMERON L, OUELLET M, WHITE B: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006; 33: 31-6.
15. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNáNDEZ-CRUZ B, RODRIGUEZ-ARBOLEYA L, NAVARRO-COMPáN V, TOYOS J: Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
16. FINCKH A, SIMARD JF, GABAY C, GUERNE PA: Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
17. BULLANO MF, McNEELEY BJ, YU YF et al.: Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006; 19: 47-53.
18. MOOTS RJ, HARAOUI B, MATUCCI-CERINIC M et al.: Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011; 29: 26-34.
19. ETEMAD L, YU EB, WANKE LA: Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005; 18: 21-7.
20. ABARCA J, MALONE DC, ARMSTRONG EP, GRIZZLE AJ, COHEN MD: Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004; 10: 538-42.
21. HARLEY CR, FRYTAK JR, TANDON N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9: S136-43.
22. WEYCKER D, YU EB, WOOLLEY JM, OSTER G: Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. Clin Ther 2005; 27: 646-56.
23. WU E, CHEN L, BIRNBAUM H, YANG E, CIFALDI M: Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008; 24: 2229-40.
24. BERGER A, EDELSBERG J, LI TT, MacLEAN JR, OSTER G: Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005; 39: 2021-5.
25. FAVALLI EG, MARCHESONI A, COLOMBO GL, SINIGAGLIA L: Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008; 26: 45-51.
26. SCHEINBERG M, GOLDENBERG J, FELDMAN DP, NOBREGA JL: Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Clin Rheumatol 2008; 27: 1049-52.
27. STERN R, WOLFE F: Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1538-45.
28. GEORGE D, KADLUBEK P, BATRA D, GOLDBERG G: Infliximab dose and charge escalation patterns in managed care. Manag Care Interface 2004; Suppl A: 5-8.
29. AGARWAL SK, MAIER AL, CHIBNIK LB et al.: Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005; 53: 872-8.
30. BLOM M, KIEVIT W, KUPER HH et al.: Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010; 62: 1335-41.
31. OLLENDORF DA, KLINGMAN D, HAZARD E, RAY S: Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009; 31: 825-35.
32. OLLENDORF DA, MASSAROTTI E, BIRBARA C, BURGESS SM: Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11: 383-93.
33. SIDIROPOULOS P, BERTSIAS G, KRITIKOS HD, KOUROUMALI H, VOUDOURIS K, BOUMPAS DT: Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004; 63: 144-8.
34. GILBERT TD, SMITH D, OLLENDORF DA: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004; 5: 36.
35. GU NY, HUANG X, FOX KM, PATEL VD, BAUMGARTNER SW, CHIOU C-F: Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010; 2: 351-9.
36. HARRISON DJ, HUANG X, GLOBE D: Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm 2010; 67: 1281-7.
37. NAIR KV, TANG B, van den BOS J et al.: Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009; 25: 303-14.
38. SCHABERT VF, BRUCE B, FERRUFINO CF et al.: Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 2012; 28: 569-80.
39. BLUME SW, FOX KM, JOSEPH G, CHUANG CC, THOMAS J, GANDRA SR: Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. Adv Ther 2013; 30: 517-27.
40. DUREZ P, van den BOSCH F, CORLUY L et al.: A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005; 44: 465-8.
41. EDREES AF, MISRA SN, ABDOU NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005; 23: 469-74.
42. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
43. van VOLLENHOVEN RF, BRANNEMARK S, KLARESKOG L: Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426-30.
44. JanSSen BIOTecH Inc.: Medication Guide: Remicade (Infliximab). Available at: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf (accessed 1 November 2013).
45. ABBVIE INC: Full Prescribing Information: Humira (Adalimumab). Available at: http://www.rxabbvie.com/pdf/humira.pdf (accessed 1 November 2013).
46. FRAZIER-MIRONER A, DOUGADOS M, MARIETTE X et al.: Retention rates of adalimumab, etanercept and infliximab as first and secondline biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 2014: 81: 352-9.
47. OGALE S, HITRAYA E, HENK HJ: Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
48. YAZICI Y, KRASNOKUTSKY S, BARNES JP, HINES PL, WANG J, ROSENBLATT L: Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009; 36: 907-13.
49. JOBANPUTRA P, MAGGS F, DEEMING A et al.: A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2012; 2: doi 10.1136/bmjopen-2012-001395.
50. SANTOLERI F, SORICE P, LASALA R, RIZZO RC, COSTANTINI A: Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. J Med Econ 2014; 17: 320-5.
51. RADSTAKE TR, SVENSON M, EIJSBOUTS AM et al.: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
52. RAHMAN MU, STRUSBERG I, GEUSENS P et al.: Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1233-8.
53. WAILOO AJ, BANSBACK N, BRENNAN A, MICHAUD K, NIXON RM, WOLFE F: Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008; 58: 939-46.
54. HEEG B, MAJER I, STEPHENS JM, TARALLO M: A model to evaluate the immunogenicity costs of tumour necrosis factor-alpha inhibitors in patients with rheumatoid arthritis. Value Health 2013; 16: A563.
55. DORE RK, MATHEWS S, SCHECHTMAN J et al.: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
56. KIM SC, YELIN E, TONNER C, SOLOMON DH: Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. Arthritis Care Res (Hoboken) 2013; 65: 1529-33.
57. BONAFEDE M, FOX KM, WATSON C, PRINCIC N, GANDRA SR: Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012; 29: 664-74.
58. EMERY P, GOTTENBERG JE, RUBBERT-ROTH A et al.: Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2014: doi 10.1136/annrheumdis-2013-203993
59. MALOTTKI K, BARTON P, TSOURAPAS A et al.: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-278.
60. MERKESDAL S, KIRCHHOFF T, WOLKA D, LADINEK G, KIELHORN A, RUBBERT-ROTH A: Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ 2010; 11: 95-104.
61. SULLIVAN SD, ALFONSO-CRISTANCHO R, CARLSON J, MALLYA U, RINGOLD S: Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ 2013; 16: 391-6.
62. GARCêS S, DEMENGEOT J, BENITO-GARCIA E: The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
63. KLOTZ U, TEML A, SCHWAB M: Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-60.
64. GEBOREK P, CRNKIC M, PETERSSON IF, SAXNE T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
65. HUANG X, GU NY, FOX KM, HARRISON DJ, GLOBE D: Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010; 26: 1637-45.
66. WENDLING D, MATERNE GE, MICHEL F et al.: Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005; 72: 309-12.
67. FLOOD J: Tumour necrosis factor inhibitors: a review of dosing patterns and related economic considerations. Managed Care 2008; 17: (Suppl. 11): P1.